Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr;22(4):283-291.
doi: 10.1038/s41571-025-00991-6. Epub 2025 Feb 11.

Artificial intelligence in digital pathology - time for a reality check

Affiliations
Review

Artificial intelligence in digital pathology - time for a reality check

Arpit Aggarwal et al. Nat Rev Clin Oncol. 2025 Apr.

Abstract

The past decade has seen the introduction of artificial intelligence (AI)-based approaches aimed at optimizing several workflows across many medical specialties. In clinical oncology, the most promising applications include those involving image analysis, such as digital pathology. In this Perspective, we provide a comprehensive examination of the developments in AI in digital pathology between 2019 and 2024. We evaluate the current landscape from the lens of technological innovations, regulatory trends, deployment and implementation, reimbursement and commercial implications. We assess the technological advances that have driven improvements in AI, enabling more robust and scalable solutions for digital pathology. We also examine regulatory developments, in particular those affecting in-house devices and laboratory-developed tests, which are shaping the landscape of AI-based tools in digital pathology. Finally, we discuss the role of reimbursement frameworks and commercial investment in the clinical adoption of AI-based technologies. In this Perspective, we highlight both the progress and challenges in AI-driven digital pathology over the past 5 years, outlining the path forward for its adoption into routine practice in clinical oncology.

PubMed Disclaimer

Conflict of interest statement

Competing interests: S. Badve is on the advisory board for Mindpeak; and is also an ad hoc adviser for Agilent, AstraZeneca, Daichii-Sanyo and Roche-Ventana. A.M. is an equity holder in Picture Health, Elucid Bioimaging and Inspirata Inc.; currently he serves on the advisory board of Picture Health; has sponsored research agreements with AstraZeneca, Boehringer-Ingelheim, Bristol Myers-Squibb and Eli-Lilly; has developed technology licensed to Picture Health and Elucid Bioimaging; is involved in two different R01 grants with Inspirata Inc.; and is a member for the Frederick National Laboratory Advisory Committee. A.A., S. Bharadwaj, G.C. and T.P. declare no competing interests.

References

    1. Rajpurkar, P., Chen, E., Banerjee, O. & Topol, E. J. AI in health and medicine. Nat. Med. 28, 31–38 (2022). - PubMed
    1. Topol, E. J. High-performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56 (2019). - PubMed
    1. Aeffner, F. et al. Introduction to digital image analysis in whole-slide imaging: a white paper from the Digital Pathology Association. J. Pathol. Inform. 10, 9 (2019). - PubMed - PMC
    1. van der Laak, J., Litjens, G. & Ciompi, F. Deep learning in histopathology: the path to the clinic. Nat. Med. 27, 775–784 (2021). - PubMed
    1. Shafi, S. & Parwani, A. V. Artificial intelligence in diagnostic pathology. Diagn. Pathol. 18, 109 (2023). - PubMed - PMC

MeSH terms

LinkOut - more resources